The short version
4 companies supply this market — a reasonable cushion if one runs into trouble.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Xeljanz Xr
tofacitinib · TOFACITINIB CITRATE 11 mg/1 · Tablet, Extended Release · Oral · U.S. Pharmaceuticals
NDC 63539-0501-30 · 30 TABLET, EXTENDED RELEASE in 1 BOTTLE · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
90-day shortage risk (model v2)
0.1%chance of a new FDA shortage posting for tofacitinib (oral solid) in the next 90 days
sole-source market
For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.
Backtested statistical model over the whole market, not this package alone. Model details →
Where it's made
- Pfizer Asia Manufacturing Pte LtdSingaporeanalysis · api manufacture
- analysis
- analysis · api manufacture
- analysis · manufacture
- analysis · label · pack
- Viatris Pharmaceuticals LLCUnited Statesanalysis · manufacture
- Viatris Pharmaceuticals LLCUnited Statesanalysis · label · pack
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $6,251.67 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA208246
- TE code
- AB
- Approval date
- Feb 23, 2016
- Patents / exclusivity
- 12 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 11253523*PED | Sep 14, 2034 |
| patent | 11253523*PED | Sep 14, 2034 |
| patent | 10639309*PED | Sep 14, 2034 |
| patent | 9937181*PED | Sep 14, 2034 |
| patent | 11253523 | Mar 14, 2034 |
| patent | 11253523 | Mar 14, 2034 |
| patent | 9937181 | Mar 14, 2034 |
| patent | 10639309 | Mar 14, 2034 |
| patent | RE41783*PED | Jun 8, 2026 |
| patent | RE41783*PED | Jun 8, 2026 |
| patent | RE41783 | Dec 8, 2025 |
| patent | RE41783 | Dec 8, 2025 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of tofacitinib (Tablet, Extended Release)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Ajanta Pharma USA Inc. | TOFACITINIB CITRATE 11 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Aurobindo Pharma Limited | TOFACITINIB CITRATE 11 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| Golden State Medical Supply, Inc. | TOFACITINIB CITRATE 11 mg/1 | Aug 12, 2026 | Sep 2, 2026 |
| U.S. Pharmaceuticals | TOFACITINIB CITRATE 11 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
| U.S. Pharmaceuticals | TOFACITINIB CITRATE 22 mg/1 | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Xeljanz Xr — NDC 63539-0501-30," retrieved September 3, 2026, https://drugdashboards.com/drug/63539050130.
Free to cite with attribution — see how the data is put together.